<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02660866</url>
  </required_header>
  <id_info>
    <org_study_id>xlpadtrace</org_study_id>
    <nct_id>NCT02660866</nct_id>
  </id_info>
  <brief_title>Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)</brief_title>
  <acronym>XLPADTRACE</acronym>
  <official_title>Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>North Texas Veterans Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>North Texas Veterans Healthcare System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 4, randomized clinical trial to evaluate whether addition of Vorapaxar 2.08&#xD;
      mg daily vs. placebo daily on background antiplatelet therapy, prescribed for 6 months to&#xD;
      patients with established peripheral artery disease (PAD) and Intermittent Claudication (IC)&#xD;
      treated with standard medical therapy (SMT) would lead to an improvement in the peak walking&#xD;
      time (PWT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary trial objective: To evaluate whether addition of Vorapaxar 2.08 mg daily vs. placebo&#xD;
      daily on background antiplatelet therapy, prescribed for 6 months to patients with&#xD;
      established PAD and IC treated with standard medical therapy (SMT) would lead to an&#xD;
      improvement in the peak walking time (PWT)&#xD;
&#xD;
      Study endpoints Primary endpoint: Change from baseline to 6 months in the PWT on a graded&#xD;
      treadmill test (GTT per Gardner protocol) between participants enrolled in the test and&#xD;
      control arms of the study&#xD;
&#xD;
      Secondary endpoints&#xD;
&#xD;
        -  Change from baseline to 6 months in the claudication onset time (COT) on GTT between&#xD;
           participants enrolled in the test and control arms of the study.&#xD;
&#xD;
        -  Change from baseline to 6 months in the walking impairment questionnaire distance scores&#xD;
           (WIQ) between participants enrolled in the test and control arms of the study.&#xD;
&#xD;
        -  Change from baseline to 6 months in self-reported quality of life score using the&#xD;
           Medical Outcomes Study 12-Item Short form survey (SF-12) between participants enrolled&#xD;
           in the test and control arms of the study&#xD;
&#xD;
      Tertiary endpoints&#xD;
&#xD;
        -  The first occurrence of clinically indicated lower extremity endovascular or surgical&#xD;
           revascularization procedure during the entire study duration post-randomization in&#xD;
           participants enrolled in the test or control arms of the study.&#xD;
&#xD;
        -  The first occurrence of all-cause death, MI, ischemic stroke during the entire study&#xD;
           duration post-randomization in participants enrolled in the test or control arms of the&#xD;
           study.&#xD;
&#xD;
        -  The first occurrence of severe bleeding defined according to the Global Utilization of&#xD;
           Streptokinase and Tissue plasminogen activator for Occluded coronary arteries (GUSTO)&#xD;
           classification during the entire study duration post-randomization in participants&#xD;
           enrolled in the test or control arms of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to 6 months in the PWT on a graded treadmill test (GTT per Gardner protocol) between participants enrolled in the test and control arms of the study</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 6 months in the claudication onset time (COT) on GTT between participants enrolled in the test and control arms of the study.</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline to 6 months in the walking impairment questionnaire distance scores (WIQ) between participants enrolled in the test and control arms of the study.&#xD;
Change from baseline to 6 months in self-reported quality of life score using the Medical Outcomes Study 12-Item Short form survey (SF-12) between participants enrolled in the test and control arms of the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>SMT+APT+Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard Medical Therapy (SMT): Presence of any two of the listed classes of agents [angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), statin therapy and beta-blocker drugs] + ability to perform at least 15 min of home walking a day, at least 3 times/week, at ≥20 steps/min&#xD;
Background Antiplatelet Therapy (APT) :At least one aspirin dose within 5 days prior to randomization at 325 mg dose in aspirin naïve patients (0-5 days of prior aspirin use) or at least one aspirin dose within 5 days prior to randomization at 81 mg dose in patients on chronic (&gt;5 days of prior use) aspirin therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SMT+APT+Vorapaxar</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Medical Therapy (SMT): Presence of any two of the listed classes of agents [angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), statin therapy and beta-blocker drugs] + ability to perform at least 15 min of home walking a day, at least 3 times/week, at ≥20 steps/min&#xD;
Background Antiplatelet Therapy (APT) :At least one aspirin dose within 5 days prior to randomization at 325 mg dose in aspirin naïve patients (0-5 days of prior aspirin use) or at least one aspirin dose within 5 days prior to randomization at 81 mg dose in patients on chronic (&gt;5 days of prior use) aspirin therapy.&#xD;
Vorapaxar: Vorapaxar 2.08mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + background APT + SMT</intervention_name>
    <description>Placebo drug therapy combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)</description>
    <arm_group_label>SMT+APT+Placebo</arm_group_label>
    <arm_group_label>SMT+APT+Vorapaxar</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorapaxar 2.08 mg/d + background APT + SMT.</intervention_name>
    <description>Vorapaxar 2.08 mg/d combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)</description>
    <arm_group_label>SMT+APT+Placebo</arm_group_label>
    <arm_group_label>SMT+APT+Vorapaxar</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Pre-screening criteria&#xD;
&#xD;
          -  Laboratory values available ≤ 1 year of the date of screening: hemoglobin ≥9g,&#xD;
             platelet count &gt;50,000 mm3 or &lt;600,000 mm3&#xD;
&#xD;
          -  No history of stroke or transient ischemic attack (TIA)&#xD;
&#xD;
          -  No allergy to aspirin&#xD;
&#xD;
          -  ≥40 years of age&#xD;
&#xD;
          -  Presence of documented PAD by ABI &lt;0.80 at rest or ≥20% drop in claudication limited&#xD;
             exercise ABI in any limb and one of the following criteria in the corresponding limb:&#xD;
&#xD;
             i.Prior surgical and/or endovascular lower extremity intervention (infra-renal aorta&#xD;
             to pedal arteries) ii. Known presence of flow-limiting stenosis (≥70%) by clinically&#xD;
             indicated angiography, computed tomographic (CT) or magnetic resonance imaging (MRI)&#xD;
             tests or by Duplex ultrasonography (DUS) defined standard clinical criteria in lower&#xD;
             extremity arteries&#xD;
&#xD;
          -  Documented IC Rutherford/Becker (RC) category ≥2&#xD;
&#xD;
          -  Presence of any one of the listed classes of agents [angiotensin converting enzyme&#xD;
             inhibitor (ACEI), angiotensin receptor blocker (ARB), lipid lowering therapy, aspirin&#xD;
             and beta-blocker drugs]-No MI or percutaneous coronary intervention (PCI) with DES&#xD;
             within the past 11 months&#xD;
&#xD;
          -  No planned surgical or endovascular procedures other than for the treatment of IC for&#xD;
             the expected duration of the study&#xD;
&#xD;
          -  No warfarin or other chronic oral anticoagulant use within the last 14 days&#xD;
&#xD;
          -  No use of ticagrelor, clopidogrel, prasugrel or ticlopidine within last 7 days&#xD;
&#xD;
          -  No contraindication(s) to the use of antithrombin or antiplatelet agents (history of&#xD;
             intra-cerebral hemorrhage or ICH, presence of intracerebral mass, recent or &lt;12 weeks&#xD;
             gastrointestinal bleed requiring blood transfusion, any blood transfusion within the&#xD;
             last 6 weeks, any trauma requiring surgery within the last 4 weeks or any surgical or&#xD;
             endovascular procedure within the last 4 weeks&#xD;
&#xD;
          -  No use of cilostazol and/or pentoxyphilline within last 7 days&#xD;
&#xD;
          -  Severe psychiatric or behavioral illness that in the judgement of the investigator&#xD;
             precludes study participation&#xD;
&#xD;
          -  No history of major or minor amputation&#xD;
&#xD;
          -  Severe heart, vascular and lung disease in the discretion of the investigator that&#xD;
             precludes study participation.&#xD;
&#xD;
          -  Ability to walk for at least 15 min/day, at least 3 days/week, at ≥20 steps/min&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          -  Treadmill PWT= 2-10 min on Gardner protocol&#xD;
&#xD;
          -  Estimated survival ≥1 year in the judgment of the site investigator&#xD;
&#xD;
          -  Use of at least one aspirin dose within at least 5 days prior to randomization at 325&#xD;
             mg dose in aspirin naïve patients (0-5 days of prior aspirin use) or at least one&#xD;
             aspirin dose prior to randomization at 81 mg dose in patients on chronic (&gt;5 days)&#xD;
             aspirin therapy (at clinically indicated doses).&#xD;
&#xD;
          -  Presence of any one of the listed classes of agents [angiotensin converting enzyme&#xD;
             inhibitor (ACEI), angiotensin receptor blocker (ARB), lipid lowering therapy, aspirin&#xD;
             and beta-blocker drugs]&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  MI or percutaneous coronary intervention (PCI) with DES within the past 11 months&#xD;
&#xD;
          -  Positive pregnancy test&#xD;
&#xD;
          -  Planned surgical or endovascular procedures other than for the treatment of IC&#xD;
&#xD;
          -  Warfarin or other chronic oral anticoagulant use within 14 days&#xD;
&#xD;
          -  Use of Ticagrelor, Clopidogrel, Prasugrel or Ticlopidine within 7 days&#xD;
&#xD;
          -  Contraindication(s) to the use of antithrombin or antiplatelet agents (history of&#xD;
             intra-cerebral hemorrhage or ICH, presence of intracerebral mass, recent or &lt;12 weeks&#xD;
             gastrointestinal bleed requiring blood transfusion, any blood transfusion within the&#xD;
             last 6 weeks, any trauma requiring surgery within the last 4 weeks or any surgical or&#xD;
             endovascular procedure within the last 4 weeks&#xD;
&#xD;
          -  Use of cilostazol and/or pentoxyphilline within 7 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ishita Tejani, BDS, MS, MSPH</last_name>
    <phone>214-857-3048</phone>
    <email>ishita.tejani@va.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southern Arizona VA Health Care System</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madhan Shanmugasundaram, MD</last_name>
      <phone>520-792-1450</phone>
      <phone_ext>4624</phone_ext>
      <email>madhan.shanmugasundaram@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Sandra Velasquez</last_name>
      <phone>520-792-1450</phone>
      <phone_ext>5691</phone_ext>
      <email>Sandra.Velasquez@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Madhan Shanmugasundaram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Diego VA Medical center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Allison, MD</last_name>
      <phone>858-552-8585</phone>
      <phone_ext>3289</phone_ext>
      <email>mallison@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amelia Parnell</last_name>
      <email>amelia.parnell@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Allison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA Eastern Colorado Healthcare System</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ehrin Armstrong, MD</last_name>
      <phone>916-762-2666</phone>
      <email>ehrin.armstrong@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Caitlin Hutchinson</last_name>
      <phone>303-399-8020</phone>
      <phone_ext>4019</phone_ext>
      <email>Caitlin.hutchinson@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Ehrin Armstrong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Heart Specialists</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30084</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Narendra Singh, MD</last_name>
      <phone>678-679-1065</phone>
      <email>disingh@ahsmed.com</email>
    </contact>
    <contact_backup>
      <last_name>Kati Raynes</last_name>
      <email>kati@ahsmed.com</email>
    </contact_backup>
    <investigator>
      <last_name>Narendra Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nedaa Skeik, MD</last_name>
      <phone>612-863-6800</phone>
      <email>nedaa.skeik@allina.com</email>
    </contact>
    <contact_backup>
      <last_name>Laura Onstot</last_name>
      <phone>612-863-6120</phone>
      <email>laura.onstot@allina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nedaa Skeik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minneapolis VA Medical center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santiago Garcia, MD</last_name>
      <phone>612-467-3670</phone>
      <email>santiago.garcia@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Rebekah Hermann, RN</last_name>
      <phone>612-467-3668</phone>
      <email>rebekah.herrmann@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Santiago Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Creighton University</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Syed Mohiuddin, MD</last_name>
      <phone>402-280-4635</phone>
      <email>smm@creighton.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brittni Gochnauer</last_name>
      <phone>402-280-4448</phone>
      <email>brittnigochnauer@creighton.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Syed Mohiuddin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell Weinberg, MD</last_name>
      <phone>516-562-4100</phone>
      <email>mweinberg@northwell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Vidya Seeratan</last_name>
      <phone>516-562-2653</phone>
      <email>vseeratan@northwell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mitchell Weinberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OKlahoma VA Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faisal Latif, MD</last_name>
      <phone>405-456-3686</phone>
      <email>faisal.latif@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Cheryl Adams, RN</last_name>
      <phone>405-456-1775</phone>
      <email>cheryl.adams@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Faisal Latif, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA Portland Health Care System</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Koopmann, MD</last_name>
      <phone>310-478-3711</phone>
      <email>matthew.koopmann@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Joy Usih</last_name>
      <phone>503-220-8262</phone>
      <phone_ext>58388</phone_ext>
      <email>joy.usih@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Koopmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA North Texas Health Care System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Subhash Banerjee, MD</last_name>
      <phone>214-857-1608</phone>
      <email>subhash.banerjee@utsouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ishita Tejani, BDS, MS, MSPH</last_name>
      <phone>214-857-3048</phone>
      <email>ishita.tejani@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Subhash Banerjee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Science Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79430</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mac Ansari, MD</last_name>
      <phone>806-743-1501</phone>
      <email>mac.ansari@ttuhsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ronnie Orozco, MS</last_name>
      <phone>806-743-6900</phone>
      <email>ronnie.orozco@ttuhsc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mac Ansari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hirsch AT, Hiatt WR; PARTNERS Steering Committee. PAD awareness, risk, and treatment: new resources for survival--the USA PARTNERS program. Vasc Med. 2001;6(3 Suppl):9-12.</citation>
    <PMID>11789964</PMID>
  </results_reference>
  <results_reference>
    <citation>McBurney CR, Eagle KA, Kline-Rogers EM, Cooper JV, Mani OC, Smith DE, Erickson SR. Health-related quality of life in patients 7 months after a myocardial infarction: factors affecting the Short Form-12. Pharmacotherapy. 2002 Dec;22(12):1616-22.</citation>
    <PMID>12495171</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>December 30, 2015</study_first_submitted>
  <study_first_submitted_qc>January 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2016</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>North Texas Veterans Healthcare System</investigator_affiliation>
    <investigator_full_name>Subhash Banerjee</investigator_full_name>
    <investigator_title>Chief, Cardiology Division</investigator_title>
  </responsible_party>
  <keyword>intermittent claudication</keyword>
  <keyword>randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Intermittent Claudication</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorapaxar</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified study results will be shared through clinicaltrials.gov and other publically available portals.</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>November 18, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

